Table 1.
C19MC miRNA differential expression in maternal circulation of PE patients.
| MiRNA | Sample | Expression | Technology | Time of Sampling | Study Type | Year |
|---|---|---|---|---|---|---|
| miR-516-5p, miR-517 *, miR-520a *, miR-525, miR-526a | Maternal plasma | Upregulated | qPCR | Third trimester | PE diagnosis | 2013 [96] |
| miR-517c, miR-518-3p, miR-518e, miR-519d | Maternal plasma | Upregulated | SOLiD™ sequencing | At delivery | PE diagnosis | 2015 [97] |
| miR-518b, miR-1323, miR-516b, miR-516a-5p, miR-525-5p, miR-515-5p, miR-520 h, miR-520a-5p, miR-519d, miR-526b | Maternal plasma | Upregulated | qPCR | 27–34 WG + | Severe PE diagnosis Early onset; late onset vs. controls | 2015 [98] |
| miR-517-5p, miR-518b, miR-520h | Maternal plasma | Upregulated | qPCR | First trimester | PE prediction | 2017 [99] |
| MiR-520g | Maternal serum | Upregulated | qPCR | First trimester | PE prediction | 2017 [68] |
| miR-517c-3p | Maternal plasma | Upregulated | qPCR | Third trimester | PE diagnosis | 2018 [70] |
| miR-520c-3p, miR-518f, miR-512-3p, miR-520d-3p | Maternal serum | Upregulated | TaqMan low density array plates | 12, 16, 20 WG + | PE prediction | 2018 [100] |
| miR-517-5p, miR-520a-5p, miR-525-5p | Plasma exosomes | Downregulated | qPCR | First trimester | PE and gestational hypertension prediction | 2019 [101] |
| miR-518b | Maternal plasma | Upregulated | ddPCR | Third trimester | PE diagnosis | 2020 [102] |
* According to the previous nomenclature [96]. + WG—weeks of gestation.